Actinogen Medical Completes Employee Share Scheme Buy-Back of 4.4 Million Shares at Nil Consideration

Sonal Goyal

12 November 2026 04:38 PM AEDT

Actinogen Medical Completes Employee Share Scheme Buy-Back of 4.4 Million Shares at Nil Consideration

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Actinogen Medical Limited (ASX:ACW) has lodged a final buy-back notification disclosing the completion of an employee share scheme buy-back involving 4,400,000 ordinary fully paid securities, with a total consideration of nil, according to a filing dated 12 November 2026.

Key Points

Actinogen Medical completed an employee share scheme buy-back of 4,400,000 ordinary fully paid shares
Total consideration paid or payable for the bought-back securities was nil
The anticipated date the buy-back occurred was 5 November 2026
The buy-back did not require securityholder approval and had no other conditions to be satisfied
Total securities on issue in the class subject to the buy-back stood at 3,874,168,325 at the time of the filing

Employee Share Scheme Buy-Back Structure

The buy-back was classified as an employee share scheme buy-back under ASX Appendix 3C requirements. According to the filing, the securities subject to the buy-back were ordinary fully paid shares trading under the ASX code ACW. The company disclosed that the buy-back did not require securityholder approval, and there were no other conditions required to be satisfied before the buy-back became unconditional. No additional information regarding the buy-back was provided by the entity beyond these disclosed details.

Final Buy-Back Notification Details

The final buy-back notification was lodged on 12 November 2026, with the initial notification of the buy-back having been made on 12 October 2026. The previous announcement to this update was also dated 12 October 2026. The filing confirms the total number of securities bought back was 4,400,000, with total consideration paid or payable recorded as zero. The securities bought back were ordinary fully paid shares, and the buy-back was described as an employee share scheme buy-back in the filing.

Securities on Issue and Buy-Back Scope

At the time of the filing, the total number of securities on issue in the class subject to the buy-back was disclosed as 3,874,168,325 ordinary fully paid shares. The 4,400,000 securities proposed to be bought back were the total number stated in the filing for the transaction. The consideration provided for the buy-back was described in the filing as nil consideration. The anticipated date on which the buy-back occurred was stated as 5 November 2026, and the filing noted no other information the entity wished to notify to ASX about the buy-back.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.